Integrated DNA Technologies and Elegen are uniting to revolutionize the long DNA synthesis market, marking the launch of ...

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

DNA (deoxyribonucleic acid ... Artificial nucleic acids with a fixed conformation of the backbone of the oligonucleotide can form stable duplexes, however, the synthesis of modified nucleotides ...

Following an extensive national search, NYU Langone Health has named Alec C. Kimmelman, MD, PhD, as its next Chief Executive ...

To achieve this workflow, we exploit the versatility of DNA oligo hybridization kinetics with DNA-PAINT probes to tailor the fluorescent blinking toward high-throughput and high-resolution imaging.

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five Duchenne trials in 2025.

Learn more about whether Alvotech or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Teacher Retirement System of Texas boosted its holdings in Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 18.9% in the 4th quarter, according to its most recent filing with the Securities and ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...